LOR.TO News 0.53 Lorus Therapeutics Inc. (LOR.TO)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lorus Therapeutics Inc. (LOR.TO) 0.53 $LOR.TO

Lorus Therapeutics Reports Third Quarter Results for Fiscal 2014
Marketwire - Thu Apr 10, 3:17PM CDT
Lorus Therapeutics Inc. (TSX: LOR) (Lorus" reported financial results for the three and nine months ended February 28, 2014 and provided an update on recent accomplishments. Unless specified otherwise, all amounts are in Canadian dollars.

Lorus Therapeutics To Host Third Quarter 2014 Financial Results Conference Call and Webcast
Marketwire - Tue Apr 08, 3:31PM CDT
Lorus Therapeutics Inc. (TSX: LOR) today announced it intends to release financial results for the quarter ended February 28, 2014, on Thursday, April 10, 2014 after the close of the market. The company intends to host a conference call on the same day at 5:00 p.m. EDT to discuss the financial results.

Lorus Therapeutics Presents Preclinical Data on LOR-253 at American Association for Cancer Research Annual Meeting 2014
Marketwire - Tue Apr 08, 3:01PM CDT
Lorus Therapeutics Inc. (TSX: LOR) today announced the presentation of preclinical data for LOR-253, the company's lead anti-cancer agent, at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego, CA. Lorus researchers demonstrated the ability of LOR-253 to induce cell death, or apoptosis, in blood cancer cell lines, including Acute Myeloid Leukemia (AML) cells, in vitro and concluded that the studies support further evaluation of LOR-253 as a potential therapy for AML and other hematologic cancers.

Lorus Therapeutics to Present Data on Lead Compound LOR-253 at AACR Annual Meeting 2014
Marketwire - Fri Apr 04, 6:01AM CDT
Lorus Therapeutics Inc. (TSX: LOR) today announced it will present preclinical data for LOR-253 in acute myeloid leukemia (AML) and other hematologic cancers at the American Association for Cancer Research (AACR) Annual Meeting 2014, to be held at the San Diego Convention Center in San Diego, CA, April 5-9, 2014.

Lorus Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Marketwire - Thu Mar 27, 4:01PM CDT
Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Company" is pleased to announce that all of the nominees listed in the management proxy circular dated February 24, 2014 were elected as directors of Lorus at the Company's annual and special meeting of shareholders held today in Toronto (the "Meeting".

IIROC Trade Resumption - LOR (all issues)
CNW Group - Thu Mar 27, 10:15AM CDT
Trading resumes in:

IIROC Trading Halt - LOR
CNW Group - Wed Mar 26, 2:38PM CDT
The following issues have been halted by IIROC:

Lorus Therapeutics Announces the Departure of Its President and Chief Operating Officer
Marketwire - Tue Mar 18, 7:24PM CDT
Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Company" announced that Dr. Aiping Young is leaving her position as President and Chief Operating Officer of Lorus, effective today. William G. Rice, Ph.D., Chairman of the Board and Chief Executive Officer of the Company, and the other members of the Company's Board of Directors, on behalf of Lorus, thank Dr. Young for her years of service to the Company and wish her well in her future endeavors. Dr. Young's responsibilities will be assumed by other members of senior management.

Lorus Therapeutics to Present at the 26th Annual ROTH Conference
Marketwire - Wed Mar 05, 6:02AM CST
Lorus Therapeutics Inc. (TSX: LOR) today announced that William G. Rice, Ph.D., Chairman and Chief Executive Officer, will present at the 26th Annual ROTH Conference at 3:00 p.m. PT on Tuesday, March 11th, 2014, in Dana Point, CA. Dr. Rice will provide a corporate overview of the Company's strategic direction including plans to develop Lorus' lead clinical agent LOR-253 for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies.

Lorus Therapeutics to Present at the RBC Capital Markets 2014 Global Healthcare Conference
Marketwire - Mon Feb 24, 6:01AM CST
Lorus Therapeutics Inc. (TSX: LOR) today announced that William G. Rice, Ph.D., Chairman and Chief Executive Officer, will present at the RBC Capital Markets 2014 Global Healthcare Conference on Wednesday, February 26th, 2014, at 3:05 p.m. ET at the New York Palace Hotel in New York City. Dr. Rice will provide a corporate overview of the Company's strategic direction including plans to develop Lorus' lead clinical agent LOR-253 for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies.

Lorus Therapeutics to Present at Biotech Showcase(TM) 2014
Marketwire - Mon Jan 13, 6:01AM CST
Lorus Therapeutics Inc. (TSX: LOR) today announced that William G. Rice, Ph.D., Chairman and Chief Executive Officer, will be presenting at Biotech Showcase 2014 on Wednesday, January 15, 2014, 4:30 pm PST at the Parc 55 Wyndham, San Francisco.

Lorus Therapeutics Inc. Announces Exercise in Full of Over-Allotment Option in Connection With Public Offering of Common Shares
Marketwire - Wed Jan 08, 8:29AM CST
Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Company" announces that the underwriters have exercised in full their over-allotment option to purchase an additional 1,909,500 common shares of the Company at a price of $0.55 per common share, in connection with the previously announced public offering of common shares of Lorus which was completed on December 10, 2013. As a result of the exercise of this over-allotment option, Lorus received additional gross proceeds of $1,050,225 and will have raised total gross proceeds of $8,051,725 from its public offering. The offering was co-led by a Clarus Securities Inc. and Canaccord Genuity Corp. and included Jennings Capital Inc. and D&D Securities Inc. as well as PowerOne Capital Markets Limited as a member of the selling group.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors, Portillo's Fraud Claims Demand Your Attention

Updated Category News Views 30

Portillo's Investors Caught in a Tough Spot Ah, Portillo's. You thought those hot dogs were the only spicy thing you're biting into? Try these allegations on for size. Investors are biting back with a securities fraud lawsuit, and the details are saltier than a bucket of fries. The folks who held PTLO shares between September 19, 2023, and May 4, 2026, are in the...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 69

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
A&G Management's Bold New Era with WPM Partnership

Updated Category News Views 122

Shaking Up Baltimore's Real Estate Scene Swapping up management partners can be a dicey game, but A&G Management seems to be pulling it off without a hitch. As of January 4, 2027, WPM Real Estate Management will take over the reins for more than 3,000 apartment homes scattered across Anne Arundel, Howard, and Baltimore counties. A new set of hands is stepping in for...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 110

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 79

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 106

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 52

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 101

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Painter's Accessory Aims to Revolutionize Convenience

Updated Category News Views 64

Crafty New Invention Targets Painters' Ease Ever find yourself tangled in paintbrushes and rollers while trying to get that perfect coat on the wall? Well, a painter from Bracebridge, Ontario, has had it with the struggle and is looking to stir the pot with their latest invention, the NU LIFE LINER. It's sleek, it's practical, and it's aimed at flipping the painting game...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 83

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

ROHM's AI-Driven Microcontrollers Revolutionize Machine Efficiency

Updated Category News Views 265

Introduction to ROHM's Innovative AI MCUs In a groundbreaking announcement, ROHM Semiconductor has unveiled a new line of microcontrollers (MCUs) equipped with advanced artificial intelligence capabilities. These AI-enabled MCUs are designed to optimize machine performance and proactively predict equipment failures by analyzing real-time data. ROHM's new technology...

Continue Reading
Nvidia Clarifies Investment Strategy Amid Market Uncertainty

Updated Category News Views 237

Nvidia Stock Reacts to New Clarifications on Investment NVIDIA Corporation (NASDAQ: NVDA) experienced a slight dip in premarket trading as investors responded to CEO Jensen Huang's recent statements about the company's potential engagement with OpenAI. Huang, addressing reporters in Taipei, clarified that the previously mentioned $100 billion was not a binding commitment...

Continue Reading
CPTx Strengthens Leadership with New CFO Appointment

Updated Category News Views 223

CPTx Welcomes McDavid Stilwell as Chief Financial Officer In a significant move to bolster its strategic and financial expertise, CPTx GmbH has appointed McDavid Stilwell as its new Chief Financial Officer (CFO). With a wealth of experience in finance and corporate strategy, Mr. Stilwell's leadership is expected to play a crucial role as the company works towards...

Continue Reading
Jupiter Neurosciences Celebrates Key Milestones in Growth Journey

Updated Category News Views 163

Jupiter Neurosciences Celebrates Key Milestones in Growth Journey Company advances JOTROL into Phase 2a Parkinson’s trial, launches Nugevia consumer brand, and strengthens financial position As Jupiter Neurosciences embarks on the journey into 2026, its first full year as a public company marks a pivotal moment. The company, known for its development of JOTROL, a...

Continue Reading
Challenges Ahead: Indian Corporate Earnings Growth Slows

Updated Category News Views 143

Indian Corporate Earnings Growth Faces Slowdown Recent insights from analysts reveal that Indian corporate earnings growth is expected to reach a three-year low. The slowdown is primarily attributed to weak performance across various sectors, as indicated in a note by Morgan Stanley. The once persistent upcycle of double-digit earnings growth appears to be stalling,...

Continue Reading